Scientific deep-dive

Do Weight-Loss Drugs Improve Natural Fertility? What the Meta-Analyses Show

GLP-1 therapy was linked to more natural pregnancies than metformin in PCOS trials, but pooled data are small, overall pregnancy did not differ significantly, and live birth benefit remains unproven. Here is what the reviews, orlistat trials and real-world records show.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
7 min read·16 citations

Weight-loss drugs may raise the chance of natural conception in women with polycystic ovary syndrome (PCOS), but the proof is thin and does not yet reach live birth. A 2026 meta-analysis of three randomized trials (252 participants) linked GLP-1-based treatment to higher odds of natural pregnancy than metformin alone (OR 3.10, 95% CI 1.74 to 5.49), with no significant difference in overall pregnancy (OR 1.41, 95% CI 0.81 to 2.45).[1] A broader review of women with overweight or obesity found seven trials, six of them on orlistat and only one on semaglutide, and most were at high risk of bias.[2] Randomized data on natural conception are close to absent for GLP-1 drugs in women without PCOS and for tirzepatide.

What the pooled analyses found

These reviews answer different questions, which is why their headlines differ. Kar and colleagues looked only at PCOS and only at GLP-1-based therapy against metformin. They rated certainty as moderate for natural pregnancy and low for overall and IVF pregnancy (OR 1.01, 95% CI 0.36 to 2.85), and they called the result a “promising preliminary” signal.[1] The abstract does not list which trials were pooled, so we can’t say how much each one drives the estimate.

Alnaimi and colleagues cast a wider net: any weight-lowering drug in women with overweight or obesity, excluding assisted reproduction. From 2,731 records they kept seven trials with 575 women. The only outcome pooled in the abstract was ovulation with orlistat versus metformin, and it showed no significant difference (RR 0.78, 95% CI 0.41 to 1.49). Of the seven trials, five were at high risk of bias and two raised some concerns.[2] The orlistat trials did not report live birth.[2]

A third meta-analysis tried to do the same for liraglutide in PCOS. Across seven randomized trials and 330 women, liraglutide increased menstrual frequency (Hedges’ g = 1.76, 95% CI 0.28 to 3.24, with high heterogeneity), but ovulation and pregnancy “could not be pooled due to insufficient reporting.”[3] So more regular periods are better documented than babies. Our guide to GLP-1s for PCOS covers the metabolic and hormonal side of that evidence.

Fertility outcomes across reviews and trials. Comparisons between rows are indirect.
SourcePopulationComparisonResult
Kar 2026, meta-analysisPCOS; 3 RCTs, 252 womenGLP-1 based therapy vs metforminNatural pregnancy OR 3.10; overall pregnancy OR 1.41 (not significant)
Alnaimi 2026, meta-analysisOverweight or obesity; 7 trials, 575 womenOrlistat vs metforminOvulation RR 0.78 (not significant)
Chen 2025, RCTPCOS; 100 randomized, 80 completedSemaglutide 1 mg plus metformin vs metforminNatural pregnancy 35% vs 15%, weeks 16 to 40
Li 2022, RCTInfertile PCOS; 160 womenExenatide vs metformin for 12 weeksSpontaneous pregnancy 29.2% vs 14.7% at week 24; total 79.2% vs 76% at week 64
FIT-PLESE 2022, RCTObesity, unexplained infertility; 379 womenMeal replacement, orlistat and activity vs activity aloneHealthy live birth 12.2% vs 15.2% (not significant)
Wu 2026, retrospective cohortInfertility; 1,936 matched womenSemaglutide in the prior year vs no semaglutideLower pregnancy and live birth (association only)

Two trials that reported natural pregnancy

In the semaglutide trial, 100 women with PCOS and overweight or obesity were randomized to metformin alone or metformin plus semaglutide 1 mg weekly for 16 weeks, and 80 completed the study. The combination group lost 6.09 kg versus 2.25 kg. Everyone then took metformin alone, and from week 16 to week 40 the natural pregnancy rate was 35% versus 15% (P < 0.05).[4] The trial was open-label. Women were told to try to conceive once semaglutide stopped at week 16, so it did not test the 2-month gap the Wegovy label asks for.[4][13]

The exenatide trial had a similar design and a useful longer view. Among 160 Chinese women with PCOS and infertility, 12 weeks of exenatide was followed by metformin alone. At week 24, 29.2% in the exenatide group had conceived spontaneously versus 14.7% on metformin (p = 0.03). By week 64, with assisted reproduction allowed, total pregnancy rates had converged at 79.2% and 76% (p = 0.65).[5] Spontaneous pregnancy tracked with weight reduction and improved insulin resistance in either group.[5] One reading is that the drug moved some conceptions earlier or spared some women a fertility procedure, without changing how many women eventually became pregnant, though the trial does not prove that.

Both drugs were stopped before the pregnancy window, so these results describe treatment before conception. They say nothing in favor of staying on a GLP-1 while trying.

Orlistat: more trials, weaker data

Orlistat dominates the older literature. In four trials it was linked to higher ovulation rates than lifestyle changes alone, but all four were at high risk of bias and the review’s authors considered their pooled result unreliable.[2] One trial reported pregnancy of 23.3% with orlistat versus 6.7% with lifestyle changes (p = 0.044).[2] A 90-woman trial in PCOS reported conception rates of 40% on orlistat and 3.3% with lifestyle changes alone over 3 months, but its ovulation difference between orlistat and metformin was not significant.[6] These groups are small, and five of the review’s seven trials were rated high risk of bias.[2]

A larger network meta-analysis of 95 trials and 9,910 women ranked combinations rather than single drugs. Exercise plus diet plus a weight-lowering drug raised ovulation compared with control (RR 4.80, 95% CI 1.67 to 13.84), though 53% of the trials carried a high or unclear risk of bias.[7] It measured ovulation, and ovulation is not the same as a baby.

Why losing weight first does not guarantee a live birth

The strongest test of the weight-loss-first idea came from FIT-PLESE, a nine-center U.S. trial of 379 women with obesity and unexplained infertility. For 16 weeks, one group used meal replacements, orlistat and more activity (weight change -6.6%), and the other added activity without weight loss (-0.3%). All were then offered three cycles of ovarian stimulation with insemination. In the intention-to-treat analysis, healthy live births were 12.2% versus 15.2% (rate ratio 0.81, 95% CI 0.48 to 1.34), with no significant difference. Metabolic syndrome improved more in the intensive group.[8] Because these women received fertility treatment, this is not a natural-conception result, but it does warn against assuming that weight loss carries through to birth.

An earlier PCOS trial of 149 women pointed the other way, weakly. Preconception weight loss, using meal replacements with sibutramine or orlistat, raised cumulative ovulation to 60% with lifestyle treatment and 67% with combined treatment versus 46% with oral contraceptives alone. Live birth rates of 26%, 24% and 12% did not reach significance (P = .13).[9] Women in that trial went on to clomiphene and timed intercourse, so this too differs from unassisted conception.

A contrary signal from real-world records

Not every study points up. A retrospective TriNetX cohort of 1,936 propensity-matched women with infertility linked semaglutide use in the year before fertility care to lower pregnancy and live birth rates, while miscarriage did not differ. Those differences were not significant in every BMI group, and hazard ratios were not consistently significant.[10] The authors state that the design “precludes causal inference,” that details of fertility treatment were unavailable, and that they could not confirm a washout.[10] Women prescribed semaglutide may also differ in ways matching can miss. Still, this is the largest single study here of pregnancy and live birth, it studied women already seeking fertility care rather than a PCOS trial group, and it is a reason not to treat the randomized signal as settled.

Who the evidence leaves out

  • Tirzepatide users. A 2026 narrative review says tirzepatide “currently has no PCOS-specific evidence,” and describes semaglutide’s conception data as preliminary. Its authors report honoraria or consulting work with GLP-1 manufacturers.[11]
  • Women without PCOS. The pooled natural pregnancy estimate comes entirely from PCOS trials.[1] Applying it to obesity-related infertility without PCOS would be an extrapolation.
  • Men. A review of male fertility found pharmacotherapy data limited to five studies of metformin and liraglutide, with insufficient data for clear conclusions and limited assessment of GLP-1 drugs.[12]

The timing and safety limits

None of these findings makes a GLP-1 a fertility drug. Wegovy’s June 2026 label says to “discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide.”[13] Zepbound’s August 2026 label says to stop “when a pregnancy is recognized” and notes that human data are insufficient to evaluate drug-related risk.[14] Our article on the 2-month washout explains where that number comes from.

Observational safety data are reassuring on one measure and unsettled on another. A meta-analysis of six studies and 286,599 women found no significant difference in major congenital malformations after periconceptional exposure (RR 1.02, 95% CI 0.96 to 1.08), and its authors warn this “should not be interpreted as proof of safety.”[15] A French study of 19,092 pregnancies with treated type 2 diabetes found no overall increase compared with insulin alone, but a possible small rise in cardiac defects in stricter analyses of GLP-1 and sulfonylurea exposure, and it concluded teratogenicity could not be excluded.[16]

Returning cycles also cut the other way for women not planning a pregnancy, since menstrual frequency and cycle recovery improved in the PCOS data.[3][4] Zepbound’s label advises people on oral contraceptives “to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”[14] We cover that in detail in our review of the tirzepatide birth control warning.

What to raise with a prescriber

  • Whether you have PCOS or another cause of infertility, since the natural pregnancy signal comes from PCOS trials.[1]
  • How long to stay on a weight-loss drug before stopping, and on what date, given the label wording for your specific drug.[13][14]
  • Whether time matters more than weight for you. FIT-PLESE spent 16 weeks on weight loss without improving live birth, and the trial did not test semaglutide or tirzepatide.[8]
  • Which contraception to use until you plan to conceive, especially if you take an oral pill with tirzepatide.[14]

Frequently Asked Questions

They may help women with PCOS conceive naturally after treatment. A 2026 meta-analysis of three randomized trials found higher odds of natural pregnancy with GLP-1-based therapy than with metformin alone (OR 3.10), but no significant difference in overall pregnancy, and the authors called the evidence preliminary. Live birth has not been established as a benefit.
One open-label trial of women with PCOS found a natural pregnancy rate of 35% after 16 weeks of semaglutide 1 mg plus metformin versus 15% with metformin alone. Semaglutide was stopped before the pregnancy window. It is one small trial and semaglutide is not approved for infertility, so this is a question for a reproductive specialist.
Several small trials linked orlistat to higher ovulation than lifestyle changes alone, but a pooled comparison with metformin found no significant difference (RR 0.78), and most of the trials were at high risk of bias. In the larger FIT-PLESE trial, a program including orlistat did not improve healthy live births.
The June 2026 Wegovy label says to stop at least 2 months before a planned pregnancy because of semaglutide's long half-life. The Zepbound label does not give the same interval and says to stop when pregnancy is recognized. Agree on a stop date with your prescriber before you start trying.

References

  1. 1.Kar E, Yeh J, Efe MA, et al. The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol. 2026. PMID: 42893679.
  2. 2.Alnaimi SJ, Alsugeir DM, Wei L, et al. Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis. Clin Obes. 2026. PMID: 42307450.
  3. 3.Lu YT, Chang PH, Chen HJ, et al. Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis. Diabetes Obes Metab. 2026. PMID: 41508932.
  4. 4.Chen H, Lei X, Yang Z, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025. PMID: 40713699.
  5. 5.Li R, Mai T, Zheng S, Zhang Y. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Arch Gynecol Obstet. 2022. PMID: 35829765.
  6. 6.Kumar P, Arora S. Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates. J Hum Reprod Sci. 2014. PMID: 25624661.
  7. 7.Ruiz-González D, Cavero-Redondo I, Hernández-Martínez A, et al. Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis. Hum Reprod Update. 2024. PMID: 38627233.
  8. 8.Legro RS, Hansen KR, Diamond MP, et al. Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial. PLoS Med. 2022. PMID: 35041662.
  9. 9.Legro RS, Dodson WC, Kris-Etherton PM, et al. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2015. PMID: 26401593.
  10. 10.Wu YC, Hsu JC, Su EC, et al. Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study. Reprod Biol Endocrinol. 2026. PMID: 42001071.
  11. 11.Jensterle M, Janez A. Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map. Drugs. 2026. PMID: 42106472.
  12. 12.Peel A, Lyons H, Tully CA, et al. The effect of obesity interventions on male fertility: a systematic review and meta-analysis. Hum Reprod Update. 2026. PMID: 41065428.
  13. 13.Novo Nordisk. WEGOVY (semaglutide) prescribing information, section 8.3. Revised June 2026. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  14. 14.Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information, sections 8.1 and 8.3. Revised August 2026. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  15. 15.Liu X, Xiong B, Yang R, et al. Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis. Endocr Connect. 2026. PMID: 42447044.
  16. 16.Collier M, Chouchana L, Kaguelidou F, et al. Safety of glucagon-like peptide-1 receptor agonists and other new-generation glucose-lowering agents for the management of type 2 diabetes in pregnancy: a French nationwide population-based study. Diabetologia. 2026. PMID: 42809004.

GLP-1 Exposure Around Conception: Birth Defect Meta-Analyses

Pooled observational data show no clear rise in major birth defects after GLP-1 exposure around conception, but certainty is very low. See what the 2026 meta-analyses found, and why one large cohort shapes the results.

9 min read

GLP-1s and Pregnancy, PCOS, and Fertility: What the FDA Labels and the Trial Evidence Actually Say

No GLP-1 label lists pregnancy as a contraindication, but all warn of fetal harm, and weight-loss labels say to stop once pregnancy is recognized. Only Wegovy and Ozempic name a 2-month pre-conception window. PCOS trials, the contraception interaction, and fertility.

13 min read

Wegovy and Pregnancy: Is Semaglutide Safe? The 2-Month Washout Rule

The current FDA Wegovy label: discontinue once pregnancy is recognized, stop at least 2 months before trying to conceive, and the injection-vs-tablet breastfeeding distinction most people miss.

13 min read

Stopping a GLP-1 Before Pregnancy: Preeclampsia and Weight Gain Evidence

Does stopping a GLP-1 before pregnancy change preeclampsia risk? Pooled data show no clear answer, while extra weight gain in pregnancy appears more consistently. What the observational studies found and why they disagree.

8 min read

Ozempic and PCOS: What the Evidence Says About Semaglutide for Polycystic Ovary Syndrome (2026)

Is Ozempic (semaglutide) approved for PCOS? No — it's off-label. What the emerging evidence shows on weight, insulin resistance, menstrual regularity, and ovulation, plus metformin comparison and the 2-month pre-pregnancy washout. An off-label, clinician-led decision.

11 min read

GLP-1 and IVF Egg Retrieval: Hold + Washout (2026)

GLP-1 and IVF involve two holds: a short anesthesia hold for egg retrieval and a longer pre-conception washout — semaglutide ≥2 months before pregnancy.

12 min read

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →